These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 18621993)

  • 1. Chemoenzymatic synthesis, characterization, and application of glycopolymers carrying lactosamine repeats as entry inhibitors against influenza virus infection.
    Hidari KI; Murata T; Yoshida K; Takahashi Y; Minamijima YH; Miwa Y; Adachi S; Ogata M; Usui T; Suzuki Y; Suzuki T
    Glycobiology; 2008 Oct; 18(10):779-88. PubMed ID: 18621993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specification of receptor-binding phenotypes of influenza virus isolates from different hosts using synthetic sialylglycopolymers: non-egg-adapted human H1 and H3 influenza A and influenza B viruses share a common high binding affinity for 6'-sialyl(N-acetyllactosamine).
    Gambaryan AS; Tuzikov AB; Piskarev VE; Yamnikova SS; Lvov DK; Robertson JS; Bovin NV; Matrosovich MN
    Virology; 1997 Jun; 232(2):345-50. PubMed ID: 9191848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoenzymatic synthesis and application of glycopolymers containing multivalent sialyloligosaccharides with a poly(L-glutamic acid) backbone for inhibition of infection by influenza viruses.
    Totani K; Kubota T; Kuroda T; Murata T; Hidari KI; Suzuki T; Suzuki Y; Kobayashi K; Ashida H; Yamamoto K; Usui T
    Glycobiology; 2003 May; 13(5):315-26. PubMed ID: 12626382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoenzymatic synthesis of sialoglycopolypeptides as glycomimetics to block infection by avian and human influenza viruses.
    Ogata M; Hidari KI; Murata T; Shimada S; Kozaki W; Park EY; Suzuki T; Usui T
    Bioconjug Chem; 2009 Mar; 20(3):538-49. PubMed ID: 19215136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy.
    Matsubara T; Onishi A; Saito T; Shimada A; Inoue H; Taki T; Nagata K; Okahata Y; Sato T
    J Med Chem; 2010 Jun; 53(11):4441-9. PubMed ID: 20476787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avian influenza A viruses differ from human viruses by recognition of sialyloligosaccharides and gangliosides and by a higher conservation of the HA receptor-binding site.
    Matrosovich MN; Gambaryan AS; Teneberg S; Piskarev VE; Yamnikova SS; Lvov DK; Robertson JS; Karlsson KA
    Virology; 1997 Jun; 233(1):224-34. PubMed ID: 9201232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoenzymatic synthesis of artificial glycopolypeptides containing multivalent sialyloligosaccharides with a gamma-polyglutamic acid backbone and their effect on inhibition of infection by influenza viruses.
    Ogata M; Murata T; Murakami K; Suzuki T; Hidari KI; Suzuki Y; Usui T
    Bioorg Med Chem; 2007 Feb; 15(3):1383-93. PubMed ID: 17129732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in receptor binding properties of recent human influenza H3N2 viruses are associated with reduced natural killer cell lysis of infected cells.
    Owen RE; Yamada E; Thompson CI; Phillipson LJ; Thompson C; Taylor E; Zambon M; Osborn HM; Barclay WS; Borrow P
    J Virol; 2007 Oct; 81(20):11170-8. PubMed ID: 17670834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities.
    Stevens J; Blixt O; Glaser L; Taubenberger JK; Palese P; Paulson JC; Wilson IA
    J Mol Biol; 2006 Feb; 355(5):1143-55. PubMed ID: 16343533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of egg-adaptation on the receptor-binding properties of human influenza A and B viruses.
    Gambaryan AS; Robertson JS; Matrosovich MN
    Virology; 1999 Jun; 258(2):232-9. PubMed ID: 10366560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological evaluation of anti-influenza viral activity of semi-synthetic catechin derivatives.
    Song JM; Park KD; Lee KH; Byun YH; Park JH; Kim SH; Kim JH; Seong BL
    Antiviral Res; 2007 Nov; 76(2):178-85. PubMed ID: 17709148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Syntheses and biological evaluations of carbosilane dendrimers uniformly functionalized with sialyl alpha(2-->3) lactose moieties as inhibitors for human influenza viruses.
    Oka H; Onaga T; Koyama T; Guo CT; Suzuki Y; Esumi Y; Hatano K; Terunuma D; Matsuoka K
    Bioorg Med Chem; 2009 Aug; 17(15):5465-75. PubMed ID: 19589684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of influenza virus infections by sialylgalactose-binding peptides selected from a phage library.
    Matsubara T; Sumi M; Kubota H; Taki T; Okahata Y; Sato T
    J Med Chem; 2009 Jul; 52(14):4247-56. PubMed ID: 19558186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The structure and receptor binding properties of the 1918 influenza hemagglutinin.
    Gamblin SJ; Haire LF; Russell RJ; Stevens DJ; Xiao B; Ha Y; Vasisht N; Steinhauer DA; Daniels RS; Elliot A; Wiley DC; Skehel JJ
    Science; 2004 Mar; 303(5665):1838-42. PubMed ID: 14764886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The quail and chicken intestine have sialyl-galactose sugar chains responsible for the binding of influenza A viruses to human type receptors.
    Guo CT; Takahashi N; Yagi H; Kato K; Takahashi T; Yi SQ; Chen Y; Ito T; Otsuki K; Kida H; Kawaoka Y; Hidari KI; Miyamoto D; Suzuki T; Suzuki Y
    Glycobiology; 2007 Jul; 17(7):713-24. PubMed ID: 17389652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of a point mutation in H5N1 avian influenza virus hemagglutinin in relation to virus entry into live mammalian cells.
    Su Y; Yang HY; Zhang BJ; Jia HL; Tien P
    Arch Virol; 2008; 153(12):2253-61. PubMed ID: 19020946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CL-385319 inhibits H5N1 avian influenza A virus infection by blocking viral entry.
    Liu S; Li R; Zhang R; Chan CC; Xi B; Zhu Z; Yang J; Poon VK; Zhou J; Chen M; Münch J; Kirchhoff F; Pleschka S; Haarmann T; Dietrich U; Pan C; Du L; Jiang S; Zheng B
    Eur J Pharmacol; 2011 Jun; 660(2-3):460-7. PubMed ID: 21536025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The human mucus protease inhibitor and its mutants are novel defensive compounds against infection with influenza A and Sendai viruses.
    Kido H; Beppu Y; Imamura Y; Chen Y; Murakami M; Oba K; Towatari T
    Biopolymers; 1999; 51(1):79-86. PubMed ID: 10380355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies differentially affect the interaction between the hemagglutinin of H9 influenza virus escape mutants and sialic receptors.
    Ilyushina N; Rudneva I; Gambaryan A; Bovin N; Kaverin N
    Virology; 2004 Nov; 329(1):33-9. PubMed ID: 15476872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Theoretical analysis of binding specificity of influenza viral hemagglutinin to avian and human receptors based on the fragment molecular orbital method.
    Iwata T; Fukuzawa K; Nakajima K; Aida-Hyugaji S; Mochizuki Y; Watanabe H; Tanaka S
    Comput Biol Chem; 2008 Jun; 32(3):198-211. PubMed ID: 18485828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.